Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets

British Journal of Cancer

Volumn 110, Issue 6, 2014, Pages 1472-1480

  Wattenberg, M M ^a   Kwilas, A R ^a   Gameiro, S R ^a   Dicker, A P ^b   Hodge, J W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

immunotherapy; monoclonal antibody; radiation; trastuzumab

Indexed keywords

CD20 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; REACTIVE OXYGEN METABOLITE; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL INTERACTION; CELL ISOLATION; CELL POPULATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL SURFACE; EMBRYO; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOGENICITY; IONIZING RADIATION; MOLECULARLY TARGETED THERAPY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RADIATION DOSE ESCALATION; RADIATION EXPOSURE; STEM CELL; THERAPY EFFECT; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL; UPREGULATION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; BREAST NEOPLASMS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MCF-7 CELLS; MOLECULAR TARGETED THERAPY; PROTEIN BIOSYNTHESIS; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

EID: 84896495551     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.79     Document Type: Article

References (41)

1. Barok M, Tanner M, Koninki K, Isola J (2011) Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res 13(2): R46.
2. Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M, Polimeni MA, Spadi R, Donadio M, Ciuffreda L, Matera L (2008) Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med 6: 25.
3. Cao DX, Qiao B, Ge ZQ, Yuan YJ (2004) Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett 214(1): 103-113.
4. Cao N, Li S, Wang Z, Ahmed KM, Degnan ME, Fan M, Dynlacht JR, Li JJ (2009) NF-kappaB-mediated HER2 overexpression in radiation-adaptive resistance. Radiat Res 171(1): 9-21.
5. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW (2003) Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. JI Immunol 170(12): 6338-6347.
6. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW (2004) External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 64(12): 4328-4337.
7. Collins DM, O'Donovan N, McGowan PM, O'Sullivan F, Duffy MJ, Crown J (2012) Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol 23(7): 1788-1795.
8. Diamant G, Dikstein R (2013) Transcriptional Control by NF-kappaB: Elongation in Focus. Biochim Biophys Acta 1829(9): 937-945.
9. Dotan E, Aggarwal C, Smith MR (2010) Impact of rituximab (Rituxan) on the treatment of B-cell non-hodgkin's lymphoma. P & T 35(3): 148-157.
10. Duru N, Fan M, Candas D, Menaa C, Liu HC, Nantajit D, Wen Y, Xiao K, Eldridge A, Chromy BA, Li S, Spitz DR, Lam KS, Wicha MS, Li JJ (2012) HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res 18(24): 6634-6647.
11. Formenti SC, Demaria S (2013) Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 105(4): 256-265.
12. Friedberg JW (2011) Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011: 498-505.
13. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW (2004) Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 64(21): 7985-7994.
14. Gavet O, Pines J (2010) Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. Dev Cell 18(4): 533-543.
15. Gelbard A, Garnett CT, Abrams SI, Patel V, Gutkind JS, Palena C, Tsang KY, Schlom J, Hodge JW (2006) Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res 12(6): 1897-1905.
16. Gloire G, Legrand-Poels S, Piette J (2006) NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 72(11): 1493-1505.
17. Hafer K, Iwamoto KS, Schiestl RH (2008) Refinement of the dichlorofluorescein assay for flow cytometric measurement of reactive oxygen species in irradiated and bystander cell populations. Radiat Res 169(4): 460-468.
18. Ithimakin S, Day KC, Malik F, Zen Q, Dawsey SJ, Bersano-Begey TF, Quraishi AA, Ignatoski KW, Daignault S, Davis A, Hall CL, Palanisamy N, Heath AN, Tawakkol N, Luther TK, Clouthier SG, Chadwick WA, Day ML, Kleer CG, Thomas DG, Hayes DF, Korkaya H, Wicha MS (2013) HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res 73(5): 1635-1646.
19. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX (2009) Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15(5): 429-440.
20. Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, Aikou T, Bates S, Fojo T (2001) Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86(7): 3430-3435.
21. Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, Mitchell T, Vaughn JP (2004) Development of Herceptin resistance in breast cancer cells. Cytometry A 57(2): 86-93.
22. Kwilas AR, Donahue RN, Bernstein MB, Hodge JW (2012) In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol 2: 104.
23. Lagadec C, Vlashi E, Della Donna L, Meng Y, Dekmezian C, Kim K, Pajonk F (2010) Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res 12(1): R13.
24. Markovic A, Chung CH (2012) Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma. Exp Rev Anticancer Ther 12(9): 1149-1159.
25. Maruyama T, Mimura K, Izawa S, Inoue A, Shiba S, Watanabe M, Kawaguchi Y, Inoue M, Nogata H, Inoue S, Fujii H, Kono K (2011) Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression. Anticancer Res 31(9): 2999-3005.
26. Mohd Sharial MS, Crown J, Hennessy BT (2012) Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol 23(12): 3007-3016.
27. Pajonk F, Vlashi E, McBride WH (2010) Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells 28(4): 639-648.
28. Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(-/low)/CD44 + breast cancer-initiating cells to radiation. J Natl Cancer Inst 98(24): 1777-1785.
29. Rajagopalan S, Willert E, Wirth R, Null W, Liu JS, Higgins JP (2013) Her2-targeted engineered toxin body demonstrates selective binding and cell kill of Her2-overexpressing breast cancer. AACR Annual Meeting: Washington DC, USA, abstract 868.
30. Reichert JM (2013) Antibodies to watch in 2013: Mid-year update. mAbs 5: 4.
31. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, van Veelen P, Neefjes JJ (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203(5): 1259-1271.
32. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9(7): 671-675.
33. Scott AM, Allison JP, Wolchok JD (2012) Monoclonal antibodies in cancer therapy. Cancer Immunity 12: 14.
34. Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y, Furukawa Y (2010) HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia 24(10): 1760-1768.
35. Stagg J, Allard B (2013) Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol 5(3): 169-181.
36. Tagliabue E, Campiglio M, Pupa SM, Menard S, Balsari A (2012) Activity and resistance of trastuzumab according to different clinical settings. Cancer Treat Rev 38(3): 212-217.
37. Tejani MA, Cohen RB, Mehra R (2010) The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biol Targets Ther 4: 173-185.
38. Tsang WP, Chau SP, Kong SK, Fung KP, Kwok TT (2003) Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci 73(16): 2047-2058.
39. Voutsas IF, Mahaira LG, Fotopoulou K, Kapranos N, Reclos JG, Gritzapis AD, Papamichail M, Perez SA, Baxevanis CN (2013) Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab. Int J Radiat Biol 89(5): 319-325.
40. Weiner LM, Dhodapkar MV, Ferrone S (2009) Monoclonal antibodies for cancer immunotherapy. Lancet 373(9668): 1033-1040.
41. Wirth R, Rajagopalan S, Willert E, Null W, Erdman J, Liu JS, Higgins JP (2013) Engineered toxin body demonstrating CD20-specific binding and cell kill in B-cell non-Hodgekin's lymphoma cells. AACR Annual Meeting: Washington DC, USA, abstract 5477.